Patents Assigned to NMD PHARMA A/S
  • Compounds for the treatment of neuromuscular disorders
    Patent number: 12168643
    Abstract: The present disclosure relates to compounds of Formula I: suitable for treating, ameliorating and/or preventing neuromuscular disorders, including the reversal of drug-induced neuromuscular blockade. The compounds as defined herein preferably inhibit the CIC-1 ion channel.
    Type: Grant
    Filed: June 19, 2020
    Date of Patent: December 17, 2024
    Assignee: NMD PHARMA A/S
    Inventors: Nicholas Kelly, Lars J.S. Knutsen, Daniel Paul Cotton
  • Compounds for the treatment of neuromuscular disorders
    Patent number: 11730714
    Abstract: The present invention relates to compounds suitable for treating, ameliorating and/or preventing neuromuscular disorders, including the reversal of drug-induced neuromuscular blockade. The compounds as defined herein preferably inhibit the CIC-1 ion channel.
    Type: Grant
    Filed: December 14, 2018
    Date of Patent: August 22, 2023
    Assignee: NMD PHARMA A/S
    Inventors: Thomas Holm Pedersen, Lars J. S. Knutsen, Nicholas M. Kelly, Martin Broch-Lips, Claus Elsborg Olesen, Marc Labelle, Ole Bækgaard Nielsen, Rajesh Kumar
  • Compounds for the treatment of neuromuscular disorders
    Patent number: 11591284
    Abstract: The present invention relates to compounds suitable for treating, ameliorating and/or preventing neuromuscular disorders, including the reversal of drug-induced neuromuscular blockade. The compounds as defined herein preferably inhibit the CIC-1 ion channel. The compounds include phenoxy propanoic acid, phenoxy propanoate, and phenoxy butanoate compounds.
    Type: Grant
    Filed: December 14, 2017
    Date of Patent: February 28, 2023
    Assignee: NMD PHARMA A/S
    Inventors: Lars J. S. Knutsen, Thomas Holm Pedersen, Claus Elsborg Olesen, Marc A. Labelle, Paul Brian Little, Martin E. Cooper, Neerja Saraswat, Dastagiri Dudekula, Rafiq A. Taj
  • COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS
    Publication number: 20220388938
    Abstract: The present disclosure relates to compounds suitable for treating, ameliorating and/or preventing neuromuscular disorders, including the reversal of drug-induced neuromuscular blockade. The compounds as defined herein can inhibit the CIC-1 ion channel.
    Type: Application
    Filed: June 19, 2020
    Publication date: December 8, 2022
    Applicant: NMD PHARMA A/S
    Inventors: Lars J.S. KNUTSEN, Nicholas KELLY, Martin Brandhøj SKOV, Anders RIISAGER, Neerja SARASWAT
  • COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS
    Publication number: 20220306564
    Abstract: The present disclosure relates to compounds of Formula I: suitable for treating, ameliorating and/or preventing neuromuscular disorders, including the reversal of drug-induced neuromuscular blockade. The compounds as defined herein preferably inhibit the CIC-1 ion channel.
    Type: Application
    Filed: June 19, 2020
    Publication date: September 29, 2022
    Applicant: NMD PHARMA A/S
    Inventors: Nicholas KELLY, Lars J.S. KNUTSEN, Daniel Paul COTTON
  • PROCESS FOR THE PREPARATION OF CLC-1 CHLORIDE CHANNEL INHIBITORS
    Publication number: 20220298124
    Abstract: This disclosure relates to an improved chemical process for making compounds which are CIC-1 chloride channel inhibitors.
    Type: Application
    Filed: June 19, 2020
    Publication date: September 22, 2022
    Applicant: NMD PHARMA A/S
    Inventors: Nicholas KELLY, Michael John MCKENZIE
  • 5-[(1S)-1-(4-BROMOPHENOXY)ETHYL]-2H-TETRAZOLE DERIVATIVES AND RELATED COMPOUNDS AS CLC-1 ION CHANNEL INHIBITORS FOR TREATING NEUROMUSCULAR DISORDERS
    Publication number: 20220274938
    Abstract: The present disclosure relates to compounds suitable for treating, ameliorating and/or preventing neuromuscular disorders, including the reversal of drug-induced neuromuscular blockade. The compounds as defined herein can inhibit the CIC-1 ion channel.
    Type: Application
    Filed: June 19, 2020
    Publication date: September 1, 2022
    Applicant: NMD PHARMA A/S
    Inventors: Lars J.S. KNUTSEN, Martin BROCH-LIPS, Martin E COOPER, Marc LABELLE, Thomas Holm PEDERSEN, Dastagiri DUDEKULA, Neerja SARASWAT, Rafiq A TAJ
  • Compounds for the treatment of neuromuscular disorders
    Patent number: 11147788
    Abstract: The present invention relates to compounds suitable for treating, ameliorating and/or preventing neuromuscular disorders, including the reversal of drug-induced neuromuscular blockade. The compounds as defined herein preferably inhibit the CIC-1 ion channel.
    Type: Grant
    Filed: December 14, 2017
    Date of Patent: October 19, 2021
    Assignee: NMD PHARMA A/S
    Inventors: Lars J. S. Knutsen, Thomas Holm Pedersen, Martin Broch-Lipps, Claus Elsborg Olesen, Marc Labelle, Ole Baekgaard Nielsen
  • Compounds for use in treating neuromuscular disorders
    Patent number: 10934244
    Abstract: The present invention relates to compositions comprising compounds for use in treating, ameliorating and/or preventing neuromuscular disorders. The compounds as defined herein preferably inhibit the ClC-1 ion channel. The invention further relates to methods of treating, preventing and/or ameliorating neuromuscular disorders, by administering said composition to a person in need thereof.
    Type: Grant
    Filed: June 15, 2016
    Date of Patent: March 2, 2021
    Assignee: NMD PHARMA A/S
    Inventors: Thomas Holm Pedersen, Martin Broch-Lips, Claus Elsborg Olesen, Marc Labelle, Ole Bækgaard Nielsen
  • Compounds for the treatment of neuromuscular disorders
    Patent number: 10385028
    Abstract: The present invention relates to compounds suitable for treating, ameliorating and/or preventing neuromuscular disorders, including the reversal of drug-induced neuromuscular blockade. The compounds as defined herein preferably inhibit the CIC-1 ion channel.
    Type: Grant
    Filed: December 14, 2017
    Date of Patent: August 20, 2019
    Assignee: NMD PHARMA A/S
    Inventors: Lars J. S. Knutsen, Martin E. Cooper, Andrew W. Brown
  • Compounds For The Treatment Of Neuromuscular Disorders
    Publication number: 20190183834
    Abstract: The present invention relates to compounds suitable for treating, ameliorating and/or preventing neuromuscular disorders, including the reversal of drug-induced neuromuscular blockade. The compounds as defined herein preferably inhibit the CIC-1 ion channel.
    Type: Application
    Filed: December 14, 2018
    Publication date: June 20, 2019
    Applicant: NMD PHARMA A/S
    Inventors: Thomas Holm Pedersen, Lars J.S. Knutsen, Nicholas M. Kelly, Martin Broch-Lips, Claus Elsborg Olesen, Marc Labelle, Ole Bækgaard Nielsen, Rajesh Kumar
  • Compounds For The Treatment Of Neuromuscular Disorders
    Publication number: 20190183863
    Abstract: The present invention relates to compounds suitable for treating, ameliorating and/or preventing neuromuscular disorders, including the reversal of drug-induced neuromuscular blockade. The compounds as defined herein preferably inhibit the CIC-1 ion channel.
    Type: Application
    Filed: December 14, 2018
    Publication date: June 20, 2019
    Applicant: NMD PHARMA A/S
    Inventors: Lars J.S. Knutsen, Nicholas M. Kelly, Thomas Holm Pedersen, Martin E. Cooper, Andrew W. Brown
  • Compounds For The Treatment Of Neuromuscular Disorders
    Publication number: 20190183812
    Abstract: The present invention relates to compounds suitable for treating, ameliorating and/or preventing neuromuscular disorders, including the reversal of drug-induced neuromuscular blockade. The compounds as defined herein preferably inhibit the CIC-1 ion channel.
    Type: Application
    Filed: December 14, 2018
    Publication date: June 20, 2019
    Applicant: NMD PHARMA A/S
    Inventors: Lars J.S. Knutsen, Nicholas M. Kelly, Thomas Holm Pedersen, Claus Elsborg Olesen, Marc Labelle, Paul Brian Little, Martin E. Cooper, Neerja Saraswat, Dastagiri Dudekula, Rafiq A. Taj